Early-Onset Alzheimer's Disease (EOAD)

Early-Onset Alzheimer's Disease (EOAD)

Early-Onset Alzheimer's Disease (EOAD)

Introduction

Early Onset [Alzheimer'S Disease](/diseases/alzheimers-disease) (Eoad) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Also known as: Early-Onset Alzheimer Disease (EOAD), Presenile Dementia, Young-Onset Alzheimer's Disease [@blood]

Definition: Early-onset Alzheimer's disease refers to Alzheimer's disease that develops before age 65, typically between 30-64 years of age. It represents approximately 5-10% of all Alzheimer's cases but accounts for a disproportionate burden of disease due to its impact on individuals in their working years.[@alzstack] [@metabolic]

Overview

Early-Onset Alzheimer's Disease (EOAD) Also known as: Early-Onset Alzheimer Disease (EOAD), Presenile Dementia, Young-Onset Alzheimer's Disease Definition: Early-onset Alzheimer's disease refers to Alzheimer's disease that develops before age 65, typically between 30-64 years of age.

Epidemiology

Early-onset Alzheimer's disease affects approximately 200,000-250,000 Americans under age 65, representing about 5-10% of the total AD population.[@blood] The prevalence increases with age: [@bloodbased]

• Under 50 years: Very rare, primarily genetic forms
• 50-59 years: ~1% of AD cases
• 60-64 years: ~5-10% of AD cases

...

Early-Onset Alzheimer's Disease (EOAD)

Early-Onset Alzheimer's Disease (EOAD)

Introduction

Early Onset [Alzheimer'S Disease](/diseases/alzheimers-disease) (Eoad) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Also known as: Early-Onset Alzheimer Disease (EOAD), Presenile Dementia, Young-Onset Alzheimer's Disease [@blood]

Definition: Early-onset Alzheimer's disease refers to Alzheimer's disease that develops before age 65, typically between 30-64 years of age. It represents approximately 5-10% of all Alzheimer's cases but accounts for a disproportionate burden of disease due to its impact on individuals in their working years.[@alzstack] [@metabolic]

Overview

Early-Onset Alzheimer's Disease (EOAD) Also known as: Early-Onset Alzheimer Disease (EOAD), Presenile Dementia, Young-Onset Alzheimer's Disease Definition: Early-onset Alzheimer's disease refers to Alzheimer's disease that develops before age 65, typically between 30-64 years of age.

Epidemiology

Early-onset Alzheimer's disease affects approximately 200,000-250,000 Americans under age 65, representing about 5-10% of the total AD population.[@blood] The prevalence increases with age: [@bloodbased]

• Under 50 years: Very rare, primarily genetic forms
• 50-59 years: ~1% of AD cases
• 60-64 years: ~5-10% of AD cases

Unlike late-onset AD, early-onset cases show no significant gender predilection, whereas late-onset AD disproportionately affects women.[@metabolic] [@abca]

Genetics and Risk Factors

Autosomal Dominant Early-Onset AD

Approximately 10-15% of early-onset AD cases are caused by autosomal dominant mutations in one of three genes:[@bloodbased] [^6]

| Gene | Chromosome | Protein | Typical Onset | Key Mutations | [^7]
|------|------------|---------|---------------|---------------| [^8]
| APP | 21q21.3 | [Amyloid Precursor Protein](/entities/app-protein) | 50-60 years | Swedish (K670N/M671L), London (V717I), Arctic (E693G) | [^9]
| [PSEN1](/entities/psen1) | 14q24.3 | Presenilin-1 | 35-55 years | Over 200 mutations identified | [^10]
| [PSEN2](/entities/psen2) | 1q42.13 | Presenilin-2 | 45-70 years | Less common than PSEN1 | [^11]

These mutations cause increased production of [amyloid-beta](/proteins/amyloid-beta) 42/40 ratio, leading to early amyloid plaque formation.[@abca] [^12]

Risk Factors for Sporadic Early-Onset AD

• Down syndrome: Trisomy 21 leads to APP overexpression; ~50% develop AD by age 60[^6]
• Head trauma: History of traumatic brain injury increases risk
• Cardiovascular risk factors: Diabetes, hypertension, hypercholesterolemia
• Education: Lower educational attainment associated with earlier onset

Clinical Presentation

Early-onset AD often presents differently than late-onset AD:[^7] [^13]

Typical Features

Memory impairment: Episodic memory loss is still the most common presenting symptom

Language difficulties: Word-finding problems and aphasia may be prominent early

Visuospatial deficits: Problems with spatial orientation and navigation

Executive dysfunction: Difficulty with planning, organization, and decision-making

Atypical Presentations (More Common in EOAD)

• Posterior cortical atrophy (PCA): Visual processing deficits, often mistaken for ocular disease[^8]
• Logopenic aphasia: Language-dominant presentation with word-finding difficulties
• Behavioral variant FTD-like: Personality changes, disinhibition (can be PSEN1-related)
• Corticobasal syndrome: Motor symptoms with asymmetric rigidity

Diagnostic Challenges

Diagnosing early-onset AD presents unique challenges:[^9] [^14]

Diagnostic Delays

• Average delay: 2-3 years from symptom onset to diagnosis
• Misdiagnosis: Often initially diagnosed as depression, stress, or other psychiatric conditions
• Younger patients: Less likely to be suspected of having AD

Diagnostic Criteria

The same core biomarkers used in late-onset AD are applicable: [^15]

CSF biomarkers: Reduced [Aβ42](/proteins/amyloid-beta), elevated total tau and phosphorylated tau[^10]

[Amyloid PET](/entities/amyloid-pet): Positive amyloid binding even in atypical presentations

[Tau](/proteins/tau) PET: Shows characteristic patterns of tau deposition

Structural MRI: Hippocampal atrophy, but may show atypical patterns

Genetic Testing

Genetic counseling and testing is recommended for:[^11]

• Patients with onset before age 50
• Family history of early-onset AD in multiple generations
• Autosomal dominant family history
• Atypical presentations with strong family history

Disease Progression

The clinical course of early-onset AD tends to be more aggressive:[^12]

| Feature | Early-Onset AD | Late-Onset AD |
|---------|----------------|---------------|
| Progression rate | Faster decline | Slower progression |
| Survival from onset | 6-8 years | 8-12 years |
| Functional impairment | More rapid | Gradual decline |
| Behavioral symptoms | Less common early | More prominent |

Treatment Approaches

FDA-Approved Therapies

All FDA-approved Alzheimer's medications are indicated for early-onset AD:[^13]

[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors):

• [Donepezil](/entities/donepezil) (Aricept)
• [Rivastigmine](/entities/rivastigmine) (Exelon)
• Galantamine (Razadyne)

[NMDA](/entities/nmda-receptor) receptor antagonist:

• Memantine (Namenda)

Disease-modifying therapies:

• [Lecanemab](/entities/lecanemab) (Leqembi) - approved for MCI due to AD and mild AD[^14]
• [Donanemab](/entities/donanemab) (Kisunla) - approved for mild cognitive impairment and mild dementia

Management Strategies

Multidisciplinary care: Neurology, psychiatry, occupational therapy

Early intervention: Earlier treatment may preserve more function

Family support: Younger patients often have dependent children

Vocational support: Employment issues, disability planning

Financial planning: Long-term care planning at younger age

Research Directions

Clinical Trials

Early-onset AD patients are underrepresented in clinical trials despite their significant disease burden.[^15] Trial inclusion criteria often exclude patients under 60-65 years, limiting generalizability.

Therapeutic Targets

Research focuses on:

Amyloid clearance: Immunotherapies particularly relevant to genetic forms

Genetic forms: PSEN1/APP mutations as models for therapeutic development

Prevention trials: DIAN-TU trial for autosomal dominant AD[^16]

Biomarker development: Earlier detection in younger patients

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Precursor Protein (APP)](/entities/app-protein)
• [Presenilin-1](/entities/psen1)
• [Presenilin-2](/entities/psen2)
• [Down Syndrome and Alzheimer's Disease](/diseases/down-syndrome-alzheimers)
• [Biomarkers in Alzheimer's Disease](/biomarkers/alzheimers-biomarkers)
• [Lecanemab](/therapeutics/lecanemab)

Background

The study of Early Onset Alzheimer'S Disease (Eoad) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [AlzStack: Forecasting early-onset Alzheimer's with an explainable AI system using multiple data balancing techniques.](https://pubmed.ncbi.nlm.nih.gov/41476457/) (2026 Jun) - Global epidemiology
• [Blood serum from individuals with Alzheimer's disease alters microglial phagocytosis in vitro.](https://pubmed.ncbi.nlm.nih.gov/40537026/) (2026 Jun 1) - Neural regeneration research
• [Metabolic breakdown: Linking insulin resistance and mitochondrial dysfunction to neurodegeneration in Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/40536952/) (2026 Jun 1) - Neural regeneration research
• [Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration.](https://pubmed.ncbi.nlm.nih.gov/41667028/) (2026 May) - Ageing research reviews
• [ABCA7 rs115550680 risk allele carriers have lower medial temporal lobe dynamic network flexibility than APOE-ε4 allele carriers among older African Americans.](https://pubmed.ncbi.nlm.nih.gov/41637763/) (2026 May) - Neurobiology of aging

References

[Unknown, AlzStack: Forecasting early-onset Alzheimer's with an explainable AI system using multiple data balancing techniques (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41476457/)

[Unknown, Blood serum from individuals with Alzheimer's disease alters microglial phagocytosis in vitro (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40537026/)

[Unknown, Metabolic breakdown: Linking insulin resistance and mitochondrial dysfunction to neurodegeneration in Alzheimer's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40536952/)

[Unknown, Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41667028/)

[Unknown, ABCA7 rs115550680 risk allele carriers have lower medial temporal lobe dynamic network flexibility than APOE-ε4 allele carriers among older African Americans (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41637763/)